Emisphere Technologies Announces Positive Results From Animal Studies on Oral B12 Using eligen(R) ...( CEDAR KNOLLS N.J. Feb. 7 /- Emisp...),Health

CEDAR KNOLLS, N.J., Feb. 7 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that recent animal studies have demonstrated proof of concept that absorption of oral vitamin B12 using the company's proprietary eligen(R) technology was 15-30 times greater than with the same dose of oral vitamin B12 administered alone. Emisphere's eligen(R) technology is the basis of the company's unique and improved delivery of therapeutic molecules and pharmaceutical compounds.

"This data demonstrates an exciting potential commercial avenue for our technology that can have a positive impact on the lives of many patients and Emisphere," said Michael V. Novinski, President and Chief Executive Officer of Emisphere.

There are at least five million people in the United States receiving 40 million B12 injections annually to treat a variety of debilitating medical conditions, and at least an additional five million people are consuming over 600 million tablets of B12 of various strengths annually. "We believe that the 40 million injections demonstrates an unmet need for an oral B12 preparation that can deliver therapeutic levels of B12 and that the megadoses being consumed as tablets are further evidence of this need," Novinski added.

The company's current timeline includes conducting clinical human trials beginning in the third quarter of 2008.

This information, and Emisphere's evolving business strategy, will be discussed during a conference call today at 10:00AM EST. The live conference call dial-in number is: 1-888-264-8952 (U.S. and Canada) or 1-913-312-0654 (International). An audio replay of the call will be available following the conference call by calling 1-888-203-1112 (U.S. and Canada) or 1
'/>"/>